<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053702</url>
  </required_header>
  <id_info>
    <org_study_id>R475-PN-0909</org_study_id>
    <nct_id>NCT01053702</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel-group, single-dose study of
      the efficacy of REGN475 in patients with pain due to thermal injury.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor decision
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in procedural pain intensity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative analgesic usage</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Patient-rated Global Impression of Change</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional quality of life assessments</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Thermal Injury Pain</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R475</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R475</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match R475 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R475</intervention_name>
    <description>IV</description>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females, ages 18 to 50, who have been hospitalized as a result of thermal
             injury

          2. Moderate to severe procedural pain intensity (during wound care) on each of the
             initial assessment days

        Exclusion Criteria:

          1. Patients with burns caused by chemical exposure or electricity

          2. Patients with inhalation injury or with evidence of pneumonia, cellulitis, or
             infection

          3. Patients with traumatic musculoskeletal injuries (eg, bone fractures or dislocations)
             or traumatic head or chest injuries

          4. Significant pre-injury concomitant illness such as, but not limited to, cardiac,
             renal, neurological, endocrinological, metabolic, psychiatric (including significant
             anxiety or depression), lymphatic disease, or drug dependence (alcohol or drug abuse),
             that would adversely affect the patient's management, recovery, or affect mortality or
             the patient's compliance with protocol assessments.

          5. Women who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Tiseo, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>April 17, 2011</last_update_submitted>
  <last_update_submitted_qc>April 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Regeneron Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

